Who Paid My Doc
Yutiq
Drug Chronic Non-infectious Posterior Segment Uveitis
NDC 71879-136-01
General payments
$1,948,514
Research payments
$2,077,151
Through program year 2023, $1,948,514 in general payments and $2,077,151 in research payments were reported against Yutiq (Chronic Non-infectious Posterior Segment Uveitis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $259,870 | 849 |
| 2023 | Research | $610,911 | 51 |
| 2022 | General | $924,911 | 1,666 |
| 2022 | Research | $625,359 | 34 |
| 2021 | General | $422,671 | 952 |
| 2021 | Research | $224,549 | 9 |
| 2020 | General | $217,155 | 460 |
| 2020 | Research | $170,517 | 2 |
| 2019 | General | $123,908 | 417 |
| 2019 | Research | $445,815 | 77 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.
The top 5 of 12 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 40 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
4,344 general · 173 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.